Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced today its scheduled presentation of the company's programs and outlook at the 14th Annual Needham Healthcare Conference on Wednesday, April …
Conatus Pharmaceuticals Inc. (NADAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today that …
Conatus Pharmaceuticals Inc (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced that it …
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced top-line results from the company's Phase 2 double-blind, placebo-controlled clinical trial of emricasan, a first-in-class, orally active …
Conatus Pharmaceuticals Inc (Nasdaq:CNAT) and its research collaborator BioReliance,Sigma-Aldrich Corporation's (Nasdaq:SIAL) biologics and early-development services business, are presenting a poster today at the …
MLV analyst Vernon Bernardino weighed in today with a few insights on Conatus Pharmaceuticals (NASDAQ:CNAT), following discussions with management during the J.P.
In a research report published Friday, Roth Capital analyst Ed Arce reiterated a Buy rating on Conatus Pharmaceuticals (NASDAQ:CNAT), but reduced his price …
MLV’s healthcare analyst Vernon Bernardino is weighing in with some thoughts on Conatus Pharmaceuticals (NASDAQ:CNAT), as the company reported aggregated topline results from phase 1 and 2 studies with …
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that aggregate top-line results from three pharmacokinetic (PK) and pharmacodynamic (PD) clinical trials in organ-impaired patients provided …
In a research report issued today, MLV analyst Vernon Bernardino maintained a Buy rating on Conatus Pharmaceuticals (NASDAQ:CNAT) with a $16 price target, ahead …
